ModerateSelective serotonin reuptake inhibitors×Amide-type local anaesthetic and class Ib antiarrhythmic (systemic use, codes C01BB01 and N01BB02)
Updated · Methodology
Mechanism
Lidocaine itself lowers the seizure threshold. According to the Spanish summary of product characteristics (SmPC) of injectable lidocaine, other drugs that lower this threshold may increase the risk of seizures (lidocaine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to its own SmPC, fluoxetine belongs to this group: seizures are among its adverse reactions, and the risk may add up with such drugs (fluoxetine SmPC, AEMPS). The liver metabolises lidocaine mainly through the enzymes CYP1A2 and CYP3A4 (lidocaine SmPC, AEMPS). Fluoxetine strongly inhibits CYP2D6. According to the US label, its inhibition of CYP3A4 is not likely to be clinically significant, and its documents do not describe CYP1A2 inhibition (fluoxetine SmPC, AEMPS; fluoxetine label, US Food and Drug Administration, FDA). QT prolongation does not apply to this pair. Among antiarrhythmics, the fluoxetine documents name only classes IA and III, and the lidocaine documents do not describe QT prolongation (fluoxetine and lidocaine documents, AEMPS and FDA).
Symptoms
Early signs of excess lidocaine in the blood are restlessness, dizziness, tinnitus, blurred vision, numbness of the tongue and around the mouth, and nausea. Shivering and muscle twitching may herald generalised seizures (lidocaine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). At higher concentrations, lidocaine depresses breathing and consciousness, even to coma. Blood pressure falls, the heart rate slows, and arrhythmias or cardiac arrest can occur (lidocaine SmPC, AEMPS). Adverse reactions may appear at plasma lidocaine levels of 5–9 mg/L, and levels above 9 mg/L often cause central nervous system toxicity (lidocaine SmPC, AEMPS). Fluoxetine itself rarely causes seizures, and in people with epilepsy seizures may become more frequent (fluoxetine SmPC, AEMPS).
Management
The combination is not contraindicated, but lidocaine and fluoxetine both lower the seizure threshold, so the risk of seizures may increase (lidocaine and fluoxetine summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). How much this matters depends on how much lidocaine reaches the blood. Absorption from cream on intact skin is very low, and blood levels stay far below toxic levels (lidocaine cream SmPC, AEMPS). With the medicated plaster, a clinically relevant pharmacokinetic interaction is unlikely (lidocaine plaster SmPC, AEMPS). For local anaesthesia by injection, give the lowest dose that produces the desired effect. Do not exceed 400 mg in a single injection into tissue with high systemic absorption. Keep resuscitation equipment ready and watch for central nervous system signs, especially in people with epilepsy (lidocaine SmPC, AEMPS). When lidocaine is given intravenously for severe ventricular arrhythmias, monitor the electrocardiogram (ECG), blood pressure, consciousness and breathing continuously, and stop the infusion at the first signs of toxicity (lidocaine SmPC, AEMPS; lidocaine label, US Food and Drug Administration, FDA). Stop fluoxetine if seizures occur or become more frequent (fluoxetine SmPC, AEMPS). Fluoxetine and its active metabolite have a long half-life, so take this into account even if fluoxetine was stopped recently (fluoxetine SmPC, AEMPS). The documents do not require a separate lidocaine dose reduction because of fluoxetine (lidocaine and fluoxetine documents, AEMPS and FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Lidocaine Hydrochloride and Dextrose Injection, USP – Prescribing Information (2026)– FDA, DailyMed SPL, Baxter Healthcare, sections Indications and Usage, Contraindications and Drug Interactions
- FDA: Prozac (fluoxetine) prescribing information (2026)– FDA label, DailyMed setid c88f33ed-6dfb-4c5e-bc01-d8e36dd97299, version 59, revised 01/2026, section 7.7 Drugs Metabolized by CYP2D6
- AEMPS: Ficha técnica: Fluoxetina, Fluoxetina Cinfa 20 mg (nº registro 63499) (2026)– AEMPS, CIMA, nº registro 63499 (Fluoxetina Cinfa 20 mg cápsulas duras EFG), revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Lidocaína – Lidocaína B. Braun 20 mg/ml (nº registro 44792), sección 4.5 (2021)– AEMPS, CIMA, nº registro 44792 (Lidocaína B. Braun 20 mg/ml solución inyectable), revisión 07/2021, secciones 4.1, 4.2, 4.4, 4.5, 4.9 y 5.2
- AEMPS: Ficha técnica: Lidocaína – Lambdalina 40 mg/g crema (nº registro 69789), sección 5.2 (2025)– AEMPS, CIMA, nº registro 69789 (Lambdalina 40 mg/g crema, Isdin), revisión 08/2025, secciones 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Lidocaína – Versatis 700 mg apósito (nº registro 71848), sección 4.5 (2019)– AEMPS, CIMA, nº registro 71848 (Versatis 700 mg apósito adhesivo medicamentoso, Grünenthal), revisión 01/2019, secciones 4.5 y 5.2